Latest news

• Elan buys into GSK-partnered Theravance programmes for $1bn

  Aside from Breo ( known as Relvar outside the US), Elan will get royalties on sales of COPD combination therapy Anoro ( umeclidinium bromide and vilanterol), vilanterol as a monotherapy and GSK961081, a

• GSK's Anoro backed in Europe for COPD

  Meanwhile, GSK and Theravance's respiratory collaboration also led to the approval of Relvar/Breo ( fluticasone/vilanterol), a direct successor to Advair. ... Both Anoro and Relvar are critical new drugs for GSK as it prepares for competition to Advair,

• GSK's Anoro first LAMA/LABA approved for COPD in US

  Important step towards eventually replacing Seretide/Advair sales

• EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

  Elsewhere, GSK followed up approval in Japan for its respiratory medicine Relvar Ellipta with a CHMP recommendation for use in asthma and COPD, while Plethora Solution's Lidocaine/ Prilocaine Plethora was backed

• Double asthma approval in Japan lifts SkyePharma

  The Japanese Ministry of Health, Labour and Welfare ( MHLW) cleared GlaxoSmithKline's ( GSK) Relvar Ellipta ( vilanterol and fluticasone), as well as Kyorin Pharmaceutical's Flutiform ( formoterol and fluticasone) for the treatment of bronchial